"Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
| Descriptor ID |
D020123
|
| MeSH Number(s) |
D02.540.505.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sirolimus".
Below are MeSH descriptors whose meaning is more specific than "Sirolimus".
This graph shows the total number of publications written about "Sirolimus" by people in this website by year, and whether "Sirolimus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 3 | 1 | 4 |
| 2004 | 3 | 2 | 5 |
| 2005 | 3 | 2 | 5 |
| 2006 | 3 | 1 | 4 |
| 2007 | 5 | 1 | 6 |
| 2008 | 4 | 5 | 9 |
| 2009 | 9 | 2 | 11 |
| 2010 | 6 | 6 | 12 |
| 2011 | 7 | 2 | 9 |
| 2012 | 4 | 8 | 12 |
| 2013 | 4 | 6 | 10 |
| 2014 | 8 | 1 | 9 |
| 2015 | 6 | 5 | 11 |
| 2016 | 5 | 3 | 8 |
| 2017 | 4 | 3 | 7 |
| 2018 | 2 | 4 | 6 |
| 2019 | 4 | 3 | 7 |
| 2020 | 0 | 4 | 4 |
| 2021 | 2 | 3 | 5 |
| 2022 | 1 | 7 | 8 |
| 2023 | 0 | 3 | 3 |
| 2024 | 5 | 2 | 7 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sirolimus" by people in Profiles.
-
Sirolimus utilization in pediatric liver transplantation: A large high-volume quaternary center experience. J Pediatr Gastroenterol Nutr. 2025 Aug; 81(2):167-176.
-
Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial. Lancet. 2025 04 26; 405(10488):1481-1490.
-
A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer. Gynecol Oncol. 2025 Feb; 193:73-80.
-
A Phase 1 Study of ABI-009 (Nab-sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors-A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514. Cancer Med. 2024 Nov; 13(21):e70376.
-
Randomized Comparison of Novel?Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs?Second-Generation DES: TARGET-IV NA Trial. J Am Coll Cardiol. 2025 Feb 18; 85(6):563-574.
-
Ex Utero Intrapartum Treatment for Prenatally Diagnosed Cervicofacial Lymphatic Malformations. J Surg Res. 2024 Nov; 303:628-635.
-
Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Lancet Oncol. 2024 Jul; 25(7):912-921.
-
Controlled Delivery of Rosuvastatin or Rapamycin through Electrospun Bismuth Nanoparticle-Infused Perivascular Wraps Promotes Arteriovenous Fistula Maturation. ACS Appl Mater Interfaces. 2024 Jul 03; 16(26):33159-33168.
-
Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update. J Clin Oncol. 2024 May 01; 42(13):1472-1476.
-
Sirolimus for vascular anomalies in the first year of life: a systematic review. J Perinatol. 2024 Aug; 44(8):1087-1097.